Polar Capital’s Coherus Oncology CHRS Stock Holding History

Polar Capital’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-15,000	Closed	-$402K	–	258
2016 Q3	$402K	Buy	+15,000	New	+$409K	0.01%	248

Other funds holding CHRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Polar Capital's CHRS Position: Q4 2016 in Review

Polar Capital sold out of Coherus Oncology (CHRS) in Q4 2016, closing a stake of 15,000 shares — an estimated $402K sold.

Polar Capital first reported a position in CHRS in Q3 2016 and held it in 1 quarter. The position peaked at $402K in Q3 2016. 122 funds tracked by Wall St. Rank hold CHRS as of Q4 2016.

Polar Capital reported no remaining Coherus Oncology position as of Q4 2016 after selling out during the quarter.
Polar Capital sold 15,000 Coherus Oncology shares in Q4 2016, an estimated $402K.
Polar Capital first reported a position in Coherus Oncology in Q3 2016 and held it in 1 quarter.
Polar Capital's Coherus Oncology position peaked at $402K in Q3 2016.
122 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2016.

Based on Polar Capital's 13F filing for Q4 2016, filed 14 Feb 2017.